Gut bacteria boosts cancer therapy? new combo trial for kidney cancer
NCT ID NCT05122546
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This early-phase study tests whether adding a gut bacteria supplement (CBM588) to standard cancer drugs (nivolumab and cabozantinib) can improve treatment for advanced kidney cancer. About 31 adults with metastatic kidney cancer will take the supplement alongside their regular therapy. The goal is to see if the supplement changes the gut microbiome and possibly helps the immune system fight the cancer better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.